skip to Main Content
Dihydroxypyrimidine Scaffold To Target HIV‑1 Nucleocapsid Protein

Dihydroxypyrimidine Scaffold to Target HIV‑1 Nucleocapsid Protein

IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new class of HIV-1 NC inhibitors. The HIV-1 nucleocapsid (NC) protein is a target of great interest because it is essential for viral replication. A bioisosteric catechol replacement approach led to identification the 5-dihydroxypyrimidine-6-carboxamide scaffold and subsequent hit validation efforts generated optimized analogs showing improved NC inhibition and antiviral activity as well as good ADME and PK properties.

Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance

Additional links for reference:

IRBM Grant funding
Cordis EU
Project website

Back To Top